Biotechnology

Scientists propose a unifying model combining 'viral mimicry' and 'cancer dark matter,' potentially revolutionizing how our immune system recognizes and fights tumors.

Tired of ineffective hair gummies? A new biotech firm backed by Khosla Ventures claims its 'pill-strength' gummy delivers real results in 30 days.

With key hires from Flatiron and Syneos, Target RWE signals major scaling plans in the booming real-world evidence market under new ownership.

Disney and Nat Geo's Earth Month campaign blends new films and park events with a 30-year, $141M conservation legacy, facing its vast environmental footprint.

As cancer strikes younger patients, a new partnership aims to find the disease before symptoms start. But is this new technology ready for prime time?

Delcath Systems is set to showcase its innovative HEPZATO KIT at SIR 2026, signaling growing adoption and a pivotal moment for its targeted cancer therapy.

With a key data readout looming for its chronic cough drug, Nocion adds a renowned dealmaker to its board, fueling speculation of a potential acquisition.

With a unique drug that preserves muscle while shedding fat, a newly fortified biotech is set to challenge the titans of the weight-loss market.

As Stryker preps its Q1 2026 report, all eyes are on whether the MedTech giant can sustain its momentum amid new products and industry-wide pressures.

In a tough biotech market, NewcelX's $1.35M financing at a 30% premium signals strong confidence in its pioneering stem cell therapy for Type 1 Diabetes.

Veteran biotech CEO Paul Sekhri joins investor Petrichor, signaling a strategic shift where hands-on leadership is now paramount in life sciences investing.

Biotech veteran Dr. Vince O'Neill joins Mosaic Therapeutics to spearhead its synergistic precision oncology pipeline, aiming to transform cancer treatment.

As China surpasses the US in key research metrics, a new English platform aims to bridge the information gap for global scientists and innovators.

A stark new benchmark study reveals poor survival in late-stage GvHD, just as MaaT Pharma’s microbiome therapy shows dramatically better outcomes.

The biopharma firm touts transformative drug data ahead, but with cash for only month-to-month operations, its future hangs by a precarious thread.

Facing a severe cash crunch and delisting threats, the biotech firm is halting development and seeking buyers for its innovative cancer drug pipeline.

OBIO awards $100K to a cancer therapy startup and launches a new training program, directly addressing the systemic funding barriers for women in life sciences.

Nominations are open for the $100,000 Fogarty Prize, continuing the mission of the late Dr. Thomas Fogarty by celebrating life-changing medical innovations.

With its lead drug for a rare pediatric liver disease entering late-stage trials, NorthSea Therapeutics adds a veteran drug developer to its board.

A novel drug aims to break down resistance in hard-to-treat lung and bile duct cancers, with key data set for a major oncology conference.